Age-Related Macular Degeneration (AMD) Market: A Global Overview
The global landscape for ocular health is currently undergoing a significant shift, primarily driven by demographic changes and technological breakthroughs in retinal care. Age-related macular degeneration (AMD) stands as a critical concern within this sector. According to market analysis by Renub Research, the global Age-Related Macular Degeneration market is projected to witness consistent growth, expanding from US$ 12.21 Billion in 2025 to US$ 23.25 Billion by 2034. This represents a steady CAGR of 7.42% during the forecast period of 2026–2034.
This growth is fueled by a confluence of factors, including the expanding geriatric population, the rising incidence of visual disorders, improvements in therapeutic delivery, and a heightened global awareness regarding the necessity of early diagnosis.
Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=age-related-macular-degeneration-market-p.php
Understanding the Condition and Its Clinical Impact
Age-related macular degeneration is a progressive ocular disease characterized by the deterioration of the macula, the specialized central region of the retina responsible for sharp, straight-ahead vision. As the condition advances, individuals experience a gradual loss of central vision, which severely compromises essential daily functions such as reading, driving, and facial recognition.
AMD is clinically classified into two primary forms:
- Dry AMD: A more common, slower-progressing form characterized by the thinning of the macula and the accumulation of drusen.
- Wet AMD: A more destructive, rapidly progressing form where abnormal new blood vessels grow beneath the retina, leading to leakage and significant vision impairment.
While there is currently no permanent cure for AMD, modern medicine offers sophisticated management strategies, including anti-vascular endothelial growth factor (anti-VEGF) injections, lifestyle modifications, and targeted nutritional supplementation.
The Global Burden: Geriatric Demographics and Prevalence
The prevalence of AMD is intrinsically linked to the aging process. As life expectancy increases globally, the segment of the population aged 60 and older is expanding rapidly. This demographic shift is particularly pronounced in developed nations across North America, Europe, and parts of Asia.
Furthermore, AMD remains a leading cause of vision impairment alongside other major ophthalmological disorders.
Global Prevalence of Ophthalmology Disorders (2025 Estimates)
| Rank | Disorder | Estimated Global Cases |
| 1 | Refractive Errors | 2.2 Billion+ |
| 2 | Presbyopia | 1.8 Billion+ |
| 3 | Dry Eye Disease | 344 Million+ |
| 4 | Age-Related Macular Degeneration (AMD) | 196 Million+ |
| 5 | Diabetic Retinopathy | 146 Million+ |
| 6 | Cataract | 94 Million+ |
| 7 | Glaucoma | 76 Million+ |
| 8 | Corneal Blindness | 12.7 Million+ |
| 9 | Trachoma | 1.9 Million (Blindness) |
| 10 | Retinitis Pigmentosa | 1.5 Million+ |
Source: WHO, global vision studies, and Renub Research
Drivers of Market Expansion
The Rising Geriatric Population
The primary engine driving the AMD market is the sheer increase in the number of individuals entering the 60+ age bracket. By 2030, one in six people worldwide will be aged 60 or older, with this population doubling to 2.1 billion by 2050. This demographic explosion ensures a sustained demand for diagnostic services and long-term therapeutic monitoring.
Advancements in Therapeutic Innovation
Pharmaceutical innovation has revolutionized AMD treatment. The advent of anti-VEGF agents provided a breakthrough in managing wet AMD, stabilizing vision for millions. Current research focus has shifted toward:
- Reduced Injection Frequency: Developing drugs that require fewer intravitreal administrations.
- Gene Therapies: Investigating long-term genetic modifications to halt disease progression.
- FDA Approvals: Significant milestones, such as the February 2025 FDA approval for the label expansion of IZERVAY™ (avacincaptad pegol), demonstrate the momentum in the sector, allowing for broader administration protocols for geographic atrophy (GA).
Enhanced Awareness and Early Detection
Public health initiatives, such as “AMD and Low Vision Awareness Month” led by organizations like Prevent Blindness, have significantly improved diagnostic rates. The integration of modern imaging technology, such as Optical Coherence Tomography (OCT) and advanced fundus imaging, allows clinicians to identify macular changes long before significant vision loss occurs, enabling timely intervention.
Market Challenges: Cost and Complexity
Despite robust growth, the market faces two significant hurdles:
- Economic Burden: The requirement for frequent, life-long intravitreal injections makes AMD management financially taxing for both healthcare systems and patients. In developing economies, the high cost of anti-VEGF therapy acts as a significant barrier to treatment adherence.
- Lack of Curative Options: The multifaceted nature of the disease makes it difficult to cure. Current treatments are largely palliative, aimed at slowing progression. This, combined with the high prevalence of dry AMD—which has fewer therapeutic options than wet AMD—remains a major gap in the medical landscape.
Segmental Analysis and Key Therapies
Dry vs. Wet AMD
Dry AMD accounts for approximately 80–90% of global cases. While it progresses more slowly, the sheer volume of patients creates a massive market for nutritional supplements and emerging complement inhibitors. Wet AMD, though less common, drives high-value utilization of specialized injectable therapies.
Key Therapeutic Profiles
- Eylea (aflibercept): Known for its high efficacy and sustained duration of action, it remains a pillar in wet AMD treatment.
- Lucentis (ranibizumab): A gold-standard pioneer in anti-VEGF therapy, maintaining a strong market share due to extensive clinical validation.
- Beovu (brolucizumab): Introduced to address the need for less frequent injections, it has carved a niche by reducing the treatment burden, though it remains under close safety monitoring regarding inflammation.
Regional Market Dynamics
- United States: The market leader, characterized by high healthcare expenditure, cutting-edge clinical research, and a sophisticated diagnostic infrastructure.
- United Kingdom: A consistent growth market supported by public health access, though it faces challenges related to hospital wait times and administrative backlogs.
- India: A high-potential growth market driven by a vast aging population. Growth is supported by the rise of private specialty eye hospitals, though rural access and treatment costs remain significant barriers.
- Saudi Arabia: Reflects a slow but steady growth trajectory, bolstered by national healthcare reforms and increased investment in advanced ophthalmological facilities.
Final Thoughts
The Age-Related Macular Degeneration (AMD) market is at a pivotal intersection of demographic inevitability and technological innovation. With a projected valuation of over US$ 23 Billion by 2034, the sector offers immense opportunities for pharmaceutical innovators and healthcare providers alike. As the world population ages, the focus must shift from purely reactionary treatment to proactive, long-term disease management. The development of sustained-release formulations and gene-based interventions will likely define the next decade of market leadership, ultimately improving the quality of life for millions of geriatric patients globally.
